Biora Therapeutics, Inc. Revenues
Biora Therapeutics, Inc. reported Revenues of $12.15 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2023-03-30
- Biora Therapeutics, Inc. revenues for the quarter ending 2022-12-31 was -$88.00K, a 101.15% decline year-over-year.
- Biora Therapeutics, Inc. revenues for the quarter ending 2022-09-30 was $10.00M, a 2.93% increase year-over-year.
- Biora Therapeutics, Inc. revenues for the quarter ending 2022-06-30 was $863.00K, a 95.39% decline year-over-year.
- Biora Therapeutics, Inc. revenues for the quarter ending 2022-03-31 was $1.38M, a 94.39% decline year-over-year.
- Biora Therapeutics, Inc. revenues for fiscal 2022 was $12.15M, a 79.95% decline from fiscal 2021.
- Biora Therapeutics, Inc. revenues for fiscal 2021 was $60.61M, a 18.44% decline from fiscal 2020.
- Biora Therapeutics, Inc. revenues for fiscal 2020 was $74.31M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $9.91M derived: sum of 2 quarters · filed 2023-03-30 | $10.78M derived: sum of 3 quarters · filed 2023-03-30 | $12.15M 10-K · filed 2023-03-30 |
| 2022-09-30 | $10.00M 10-Q · filed 2022-11-14 | $10.87M derived: sum of 2 quarters · filed 2022-11-14 | $12.24M 10-Q · filed 2022-11-14 | $19.90M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | $863.00K 10-Q · filed 2022-08-15 | $2.24M 10-Q · filed 2022-08-15 | $9.90M derived: sum of 3 quarters · filed 2023-03-30 | $19.62M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | $1.38M 10-Q · filed 2022-05-10 | $9.04M derived: sum of 2 quarters · filed 2023-03-30 | $18.75M derived: sum of 3 quarters · filed 2023-03-30 | $37.46M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $17.38M derived: sum of 2 quarters · filed 2023-03-30 | $36.08M derived: sum of 3 quarters · filed 2023-03-30 | $60.61M 10-K · filed 2023-03-30 |
| 2021-09-30 | $9.72M 10-Q · filed 2022-11-14 | $28.42M derived: sum of 2 quarters · filed 2022-11-14 | $52.95M 10-Q · filed 2022-11-14 | $67.22M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $18.70M 10-Q · filed 2022-08-15 | $43.23M 10-Q · filed 2022-08-15 | $57.51M derived: sum of 3 quarters · filed 2022-08-15 | $83.45M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $24.53M 10-Q · filed 2022-05-10 | $38.80M derived: sum of 2 quarters · filed 2022-05-10 | $64.75M derived: sum of 3 quarters · filed 2022-05-10 | $82.01M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $14.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $40.22M derived: sum of 2 quarters · filed 2022-03-28 | $57.48M derived: sum of 3 quarters · filed 2022-03-28 | $74.31M 10-K · filed 2022-03-28 |
| 2020-09-30 | $25.94M 10-Q · filed 2021-11-10 | $43.21M derived: sum of 2 quarters · filed 2021-11-10 | $60.04M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $17.27M 10-Q · filed 2021-08-12 | $34.09M 10-Q · filed 2021-08-12 |